Identification Of FH Causing Mutations/SNPs In Malaysian Population Habitats | 8505
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Identification of FH causing mutations/SNPs in Malaysian population habitats

World Congress on Biotechnology

Livy Alex, Jagdish Kaur Chahil, Lye Say Hean, Ler Lian Wee and Pramod Bagali

ScientificTracks Abstracts: J Biotechnol Biomaterial

DOI: 10.4172/2155-952X.1000001

Familial hypercholesterolemia (FH, ICD-10 code E78.0) is an autosomal dominant disorder that causes severe elevations in total plasma cholesterol and low density lipoprotein cholesterol (LDLC), and is associated with a high risk for premature coronary artery disease (CAD). It is caused mainly by mutations, single nucleotide polymorphisms (SNPs), large deletions or insertions in the LDLR, APOB or PCSK9 genes. Over 1,500 genetic variants have been identified in the LDLR gene so far, as reported by British Heart Foundation (BHF) based on studies done mainly in the Caucasian population. However, there are not many genetic variants of LDLR gene documented in Malaysian population. The current method of FH diagnosis is based on clinical criteria, which only make the diagnosis when the disease is at an advanced stage. In the present study, we are investigating the FH-causing genetic variants on LDLR in Malaysian cohort. Thus far, we have identified eight single nucleotide mutations/SNPs in clinically diagnosed FH patients by DNA sequencing. The eventual goal of the project is to devise a microarray-based diagnostic tool which will aid in the screening and early diagnosis of Malaysian FH patients, and thus providing a more effective means for disease management.
Dr. Livy Alex has completed her Ph.D in 1994 from the Department of Microbiology, Osmania University, India and was a post-doctoral fellow at the Centre for Cellular and Molecular Biology, Hyderabad, India. Thereafter she joined the biotechnology industry and worked for Sudershan Biotech Pvt., Ltd, Hyderabad(1999-2003), Reliance Life Sciences, Mumbai(2003-2007) and Actis Biologics, Mumbai, India(2007-2008). At present, she heads the Molecular Research Labs at INFOVALLEY Group of Companies (Malaysia/India). Her research interests are human genomics, recombinant proteins, molecular diagnostics, and yeast biotechnology. She has a few patents to her credit and is currently involved in developing diagnostic microarray chips for complex inherited diseases.